STOCK TITAN

RenovoRx director Richard Stark reports stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

RenovoRx, Inc. director Richard Stark reported directly held, fully vested and exercisable stock options on November 18, 2026. The options cover 46,000 common shares at an exercise price of $1.38 per share, expiring December 4, 2034; 12,000 shares at $1.02 per share, expiring January 5, 2036; and 50,000 shares at $0.98 per share, expiring April 2, 2036. They were granted under the issuer’s Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services.

Insider Stark Richard
Role Director
Type Security Shares Price Value
Holding Stock Option (right to buy) F1 -- -- --
Holding Stock Option (right to buy) F1 -- -- --
Holding Stock Option (right to buy) F1 -- -- --
Holdings: Stock Option (right to buy) — 108,000 options (Direct)
Footnotes (1)
  1. F1. The options were granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services provided to the Issuer and are fully vested and exercisable.
Underlying common shares 46,000 shares Direct stock options; exercise price $1.38 per share; expiration December 4, 2034.
Exercise price $1.38 per share Options covering 46,000 common shares; expiration December 4, 2034.
Underlying common shares 12,000 shares Direct stock options; exercise price $1.02 per share; expiration January 5, 2036.
Exercise price $1.02 per share Options covering 12,000 common shares; expiration January 5, 2036.
Underlying common shares 50,000 shares Direct stock options; exercise price $0.98 per share; expiration April 2, 2036.
Exercise price $0.98 per share Options covering 50,000 common shares; expiration April 2, 2036.
Amended and Restated 2021 Omnibus Equity Incentive Plan technical
"granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did RenovoRx director Richard Stark report?

Richard Stark reported options covering 46,000 shares at $1.38, 12,000 shares at $1.02, and 50,000 shares at $0.98. The options expire December 4, 2034, January 5, 2036, and April 2, 2036, respectively. They were granted under RenovoRx’s Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Stark Richard

(Last)(First)(Middle)
C/O RENOVORX, INC.
2570 W EL CAMINO REAL, SUITE 640

(Street)
MOUNTAIN VIEW CALIFORNIA 94040

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/18/2026
3. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (1)12/04/2034Common Stock46,000$1.38D
Stock Option (right to buy) (1)01/05/2036Common Stock12,000$1.02D
Stock Option (right to buy) (1)04/02/2036Common Stock50,000$0.98D
Explanation of Responses:
1. The options were granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services provided to the Issuer and are fully vested and exercisable.
/s/ Richard Stark11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading